<DOC>
	<DOCNO>NCT01945489</DOCNO>
	<brief_summary>This study evaluate efficacy safety onabotulinumtoxinA ( BOTOX® ) compare placebo , achieve 100 % reduction urinary incontinence patient overactive bladder ( OAB ) properly manage anticholinergic .</brief_summary>
	<brief_title>OnabotulinumtoxinA ( BOTOX® ) Treatment Urinary Incontinence Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients symptom Overactive Bladder ( OAB ) ( frequency urgency ) urinary incontinence least 6 month prior screen . Symptoms OAB due neurological reason Use anticholinergic medication therapy treat symptom OAB within 7 day screen Use Clean Intermittent Catheterization ( CIC ) indwell catheter manage urinary incontinence Use botulinum toxin therapy serotype urological condition Use botulinum toxin therapy serotype nonurological condition 12 week prior screen History pelvic urological abnormality , bladder surgery disease , OAB , may affect bladder function Diagnosis Myasthenia gravis , EatonLambert syndrome , Amyotrophic Lateral Sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>